Pancreatic Cancer Research

ResearcherCambridge University Hospitals NHS Foundation TrustActive in the last 2 years

Rebecca J. Brais

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0006-7848-5994; OpenAlex author ID A5036862189. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
40
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 2 papers · 2026: 2 papers

Papers 9

  1. Multi-stromal organoid co-culture modelling reveals epithelial-fibroblast heterogeneity in pancreatic cancer and pancreatitis. Co-author DOI 10.1038/s41556-026-02057-w↗
  2. Cross-species graph-embedding unmasks the ageing microenvironment as a key determinant of pancreatic cancer malignant cell biology and therapy response Co-author DOI 10.64898/2026.02.02.703350↗
  3. Transcription factor switching drives subtype-specific pancreatic cancer. Co-author DOI 10.1038/s41588-025-02389-7↗
  4. SMAD4 and KRAS Status Shapes Cancer Cell-Stromal Cross-Talk and Therapeutic Response in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-24-2330↗
  5. Defining the spatial distribution of extracellular adenosine revealed a myeloid-dependent immunosuppressive microenvironment in pancreatic ductal adenocarcinom… Co-author DOI 10.1136/jitc-2022-006457↗
  6. Method To Visualize the Intratumor Distribution and Impact of Gemcitabine in Pancreatic Ductal Adenocarcinoma by Multimodal Imaging. Co-author DOI 10.1021/acs.analchem.1c04579↗
  7. Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. Co-author DOI 10.1038/s41416-020-0846-2↗
  8. Endothelin-1 and endothelin B receptor expression in pancreatic adenocarcinoma. First author DOI 10.1136/jclinpath-2014-202521↗
  9. Direct histological processing of EUS biopsies enables rapid molecular biomarker analysis for interventional pancreatic cancer trials. Co-author DOI 10.1016/j.pan.2011.12.009↗

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Joaquín Araos Henríquez · 3 shared papers, 2025–2026 · strength 0.65
  2. Priscilla S.W. Cheng · 3 shared papers, 2025–2026 · strength 0.65
  3. Eloise G. Lloyd · 3 shared papers, 2025–2026 · strength 0.65
  4. Wenlong Li · 3 shared papers, 2025–2026 · strength 0.65
  5. Gianluca Mucciolo · 3 shared papers, 2025–2026 · strength 0.65
  6. Giulia Biffi · 3 shared papers, 2025–2026 · strength 0.65
  7. Duncan Ian Jodrell · 5 shared papers, 2012–2025 · strength 0.52
  8. Bristi Basu · 2 shared papers, 2020–2026 · strength 0.29
  9. Brajesh Pratap Kaistha · 2 shared papers, 2022–2023 · strength 0.25
  10. Frances M. Richards · 2 shared papers, 2022–2023 · strength 0.25
  11. Debasmita Mukherjee · 1 shared paper, 2026 · strength 0.23
  12. Vincenzo Corbo · 1 shared paper, 2025 · strength 0.20
  13. Lisa Veghini · 1 shared paper, 2025 · strength 0.20
  14. Aarthi Gopinathan · 2 shared papers, 2020–2022 · strength 0.18
  15. Hideo Baba · 1 shared paper, 2025 · strength 0.17
  16. Phyllis F. Cheung · 1 shared paper, 2025 · strength 0.17
  17. Barbara T. Grünwald · 1 shared paper, 2025 · strength 0.17
  18. Niklas Krebs · 1 shared paper, 2025 · strength 0.17
  19. Shalini V. Rao · 1 shared paper, 2025 · strength 0.17
  20. Jason S. Carroll · 1 shared paper, 2025 · strength 0.17
  21. Jens Thomas Siveke · 1 shared paper, 2025 · strength 0.17
  22. Pippa G. Corrie · 3 shared papers, 2012–2020 · strength 0.16
  23. Vincenzo Graziano · 1 shared paper, 2023 · strength 0.14
  24. Jennifer P. Morton · 1 shared paper, 2023 · strength 0.14
  25. James E. D. Thaventhiran · 1 shared paper, 2023 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.